Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Study of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CD20 - Cluster of Differentiation Antigen 20)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04007029
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:22.050469+00:00
Published At
2025-09-05T00:00:00+00:00
Record Updated At
2025-09-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["CD19 Positive", "CD20 Positive", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Refractory Small Lymphocytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-05"
protocolSection.identificationModule.nctId
"NCT04007029"
protocolSection.identificationModule.officialTitle
"Study of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CD20 - Cluster of Differentiation Antigen 20)"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • CD19 Positive (protocolSection.conditionsModule.conditions)
  • CD20 Positive (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.